View More Recent Stories

May 18, 2021 07:30AM Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:30AM Mydecine to Participate in the Benzinga Global Small Cap Conference on May 13th
May 5, 2021 07:30AM Mydecine Announces Partnership with LeadGen Labs
May 3, 2021 07:30AM Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Apr 26, 2021 07:30AM Mydecine to Report Full Year 2020 Financial Results on May 3, 2021
Apr 13, 2021 07:30AM Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
Apr 7, 2021 07:30AM Mydecine Announces API-naming structure of Four Lead Candidates and Prepares for Pre-IND
Apr 7, 2021 07:30AM Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
Mar 23, 2021 09:30AM Mydecine Innovations Group Graduates Listing To NEO Exchange
Mar 23, 2021 07:30AM Mydecine Innovations Group Announces Migration to NEO Exchange
Mar 16, 2021 07:30AM Mydecine Innovations Group Provides Update on European Operations
Mar 1, 2021 07:30AM Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Feb 12, 2021 09:08AM Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Feb 9, 2021 02:29PM Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units
Feb 5, 2021 08:06AM Mydecine Innovations Group Files Amended and Restated Financial Statements
Feb 3, 2021 07:30AM Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
Feb 1, 2021 07:30AM Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
Jan 28, 2021 07:30AM Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
Jan 27, 2021 07:30AM Mydecine Innovations Group Files Application to list to the NASDAQ
Jan 22, 2021 07:30AM Mydecine Innovations Group Included in First-Ever Psychedelics ETF
Jan 21, 2021 04:20PM Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units
Jan 20, 2021 11:00AM Mydecine Innovations Group Upsizes Previously Announced Bought Deal
Jan 20, 2021 10:58AM Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Jan 11, 2021 07:30AM Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Jan 7, 2021 07:30AM Mydecine Innovations Group Shares Intellectual Property Update
Jan 5, 2021 07:30AM Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
Dec 21, 2020 07:30AM Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
Dec 15, 2020 07:30AM Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
Dec 10, 2020 07:30AM Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
Dec 8, 2020 07:30AM Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Nov 24, 2020 01:23AM Mydecine Innovations Group to Restate Financial Statements
Nov 17, 2020 08:00AM Mydecine Innovations Group Offers Management and Clinical Trials Update
Nov 6, 2020 08:30AM Mydecine Innovations Group Retains KCSA Strategic Communications
View More Recent Stories